Company: ARWR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038858
Chunk: 80

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 8
Chunk 80
---
,746 $1,938 $(105)$770,579 As of September 30, 2024(in thousands)Adjusted BasisGrossUnrealized GainsGrossUnrealized LossesFair ValueAvailable-for-sale securities$577,465 $837 $(26)$578,276 Total current investments$577,465 $837 $(26)$578,276 The following table summarizes the contract maturity of the available-for-sale securities as of:   June 30, 2025September 30, 2024(in thousands)Within one year$224,571 $578,276 After one to two years450,889 — After two to three years95,119 — Total$770,579 $578,276 

As of June 30, 2025 and September 30, 2024, the gross unrealized losses were immaterial. The Company has determined that the available-for-sale securities that were in an unrealized loss position did not have any credit loss impairment as of June 30, 2025 and 2024. 

13

NOTE 5. INTANGIBLE ASSETS

Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: Gross Carrying AmountAccumulated AmortizationImpairmentNet Carrying AmountUseful Lives(in thousands)(in years)As of June 30, 2025Patents$21,728 $16,037 $— $5,691 14License3,129 1,534 — 1,595 21Total intangible assets, net$24,857 $17,571 $— $7,286 As of September 30, 2024Patents$21,728 $14,873 $— $6,855 14License3,129 1,422 — 1,707 21Total intangible assets, net$24,857 $16,295 $— $8,562 Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the nine months ended June 30, 2025 and 2024.Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amort